HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Compared with systemic intravenous chemotherapy, hepatic arterial infusion chemotherapy(HAIC) has the advantages of increasing local drug concentration and reducing systemic toxic and side effects. All patients were treated with HAIC (Oxaliplatin and Raltitrexed ). Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time； Tislelizumab was given 200mg every 3 weeks. The treatment continued until the patient developed the disease or met the other criteria for terminating the study.

Inclusion criteria

• Written informed consent for the trial.
• Aged ≥18 years.
• Histologically confirmed intrahepatic cholangiocarcinoma.
• No other previous systematic treatment for BTC.
• At least one measurable lesion (RECIST 1.1).
• Eastern Cooperative Oncology Group performance status 0 or 1.
• Life expectancy of 3 months or greater.
• Child-Pugh classification score ≤7.

Exclusion criteria

• Recurrent patients.
• Eastern Cooperative Oncology Group performance status ≥ 2.
• Life expectancy of less than 3 months.
• Child-Pugh classification score > 8.
• History of hepatic encephalopathy or liver transplantation.
• Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation.
• Symptomatic pleural effusion, ascites, and pericardial effusion that require drainage.
• Portal vein tumor thrombus (PVTT) involves both the main trunk and contralateral branch or upper mesenteric vein. Inferior vena cava tumor thrombus.
• Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-CTLA4, etc.).
• History of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis.
• The researcher considers it inappropriate to enter this study.